




Smartphone-enabled optofluidic exosome diagnostic for concussion recovery

Jina Ko¹, Matthew A. Hemphill¹, David Gabrieli¹, Leon Wu¹, Venkata Yelleswarapu¹, Gladys Lawrence¹, Wesley Pennycooke¹, Anup Singh¹, Dave Meaney^{1*}, David Issadore^{1,2*}

1. Department of Bioengineering, School of Engineering and Applied Sciences, University of Pennsylvania. Philadelphia, Pennsylvania, United States.
2. Department of Electrical and Systems Engineering, School of Engineering and Applied Sciences, University of Pennsylvania. Philadelphia, Pennsylvania, United States.

* equal contribution

Disposable microchip

		
<p>Top view. The microchip consists of reservoir, porous membrane, and output port.</p>	<p>Side view. The top layer of the microchip is fabricated with angles for total internal reflection.</p>	<p>3D image. The microchip is disposable, made of PDMS, and is similarly sized as US quarter dollar.</p>

μ MED

3D printed device




		
<p>Top view. The 3D printed device consists of a bandpass filter (green) and a dichroic filter (red) for detection.</p>	<p>Bottom view. The microchip slides into the 3D printed device and the door is closed to prevent background light.</p>	<p>3D image. The 3D printed device holds both the smartphone and the microchip that allows smartphone-based optofluidic diagnostic.</p>

Figure S1. Computer Assisted Design (CAD) drawings of our μ MED device.




Figure S2. Validation of antibody specific capture and labeling. **a.** We validated the specificity of our antibody based capture and labeling using $V = 1$ mL of cultured media from our cortical neuron *in vitro* model. To test if the CD81 microbead capture of exosomes is specific, we replaced the CD81 pan exosome antibody with a control antibody (purified rabbit polyclonal Isotype control antibody) and saw a significant reduction in μ MED's signal (MFI). To test if the labeling of our exosomes with GluR2 is specific, we replaced the GluR2 antibody with a control antibody (purified rabbit polyclonal Isotype control antibody) and saw a significant reduction in signal in μ MED's signal (MFI). **b.** We performed the same experiment, and saw similar results validating the specificity of our capture and labeling, using 100 μ L of serum from our *in-vivo* murine model.




Figure S3. Characterization of isolated exosomes. **a.** A cryological Transmission Electron Microscope (cryo-TEM) micrograph of individual exosomes bound to the CD-81 functionalized 2.2 μm polystyrene bead used to capture it. The exosomes were captured from cultured cortical neuron cultured media. **b.** cryo-TEM imaging on exosomes eluted from those microbeads onto a TEM grid. **c.** Nanoparticle Tracking Analysis (NTA) data of exosomes from unprocessed cortical cell culture media. **d.** NTA data of the exosomes captured by our microbead system and then eluted for NTA measurement.




Figure S4. Measurement of GluR2+ exosomes after injury using conventional methods. a. To validate the results of μ MED, exosomes were isolated using a conventional size-based method and their protein content was profiled using Western Blotting. **b.** Quantification of the Flotillin level (total exosome) for (N=6) injured and (N=6) uninjured controls, showing no significant difference. **c.** Quantification of the GluR2 level normalized by the total exosome level (Flotillin-1) for (N=6) injured and (N=6) uninjured controls, showing significant difference.




Figure S5. Western blotting on exosomes eluted from anti-CD45/CD61 beads and anti-CD81 beads. Western blotting was performed on exosomes isolated using both positive selection beads (CD81) and negative selection beads (CD45/CD61) from mouse serum. Exosomes eluted from the two bead populations were analyzed for CD45 and CD61, as well as the pan-exosome marker CD81.